Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers

References

• Dal Piaz F, Vassallo A, Temraz A, et al. A chemical-biological study reveals C-9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors. J Med Chem 2013;56:1583–95
   PubMed Web of Science ®Google Scholar
• Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010;11:515–28
   PubMed Web of Science ®Google Scholar
• Mashaghi A, Kramer G, Lamb DC, et al. Chaperone action at the single-molecule level. Chem Rev 2014;114:660–76
   PubMed Web of Science ®Google Scholar
• Saxena V, Naguib Y. Hussain MD, Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer. Colloid Surface B 2012;94:274–80
   PubMed Web of Science ®Google Scholar
• DeBoer C, Meulman PA, Wnuk RJ, et al. Geldanamycin, a new antibiotic. J Antibiot 1970;23:442–7
   PubMed Web of Science ®Google Scholar
• Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239–50
   PubMed Web of Science ®Google Scholar
• Abramson JS, Chen W, Juszczynski P, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haematol 2009;144:358–66
   PubMed Web of Science ®Google Scholar
• An WG, Schnur RC, Neckers L, et al. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 1997;40:60–4
   PubMed Web of Science ®Google Scholar
• Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361–73
   PubMed Web of Science ®Google Scholar
• Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anti-cancer activities. Cancer Lett 2010;290:24–35
   PubMed Web of Science ®Google Scholar
• Kitson RRA, Chang CH, Xiong R, et al. Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat Chem 2013;5:307–14
   PubMed Web of Science ®Google Scholar
• Kitson RRA, Moody CJ. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors – potential therapeutics in cancer and neurodegeneration. Chem Commun 2013;49:8441–3
   PubMed Web of Science ®Google Scholar
• Tian ZQ, Wang Z, MacMillan KS, et al. Potent cytotoxic C-11 modified geldanamycin analogues. J Med Chem 2009;52:3265–73
   PubMed Web of Science ®Google Scholar
• Rastelli G, Tian ZQ, Wang Z, et al. Structure-based design of 7-carbamate analogs of geldanamycin. Bioorg Med Chem Lett 2005;15:5016–21
   PubMed Web of Science ®Google Scholar
• Tian ZQ, Liu YQ, Zhang D, et al. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorgan Med Chem 2004;12:5317–29
   PubMed Web of Science ®Google Scholar
• Kasuya Y, Lu ZR, Kopeckova P, et al. Improved synthesis and evaluation of 17-substituted aminoalkylgeldanamycin derivatives applicable to drug delivery systems. Bioorg Med Chem Lett 2001;11:2089–91
   PubMed Web of Science ®Google Scholar
• Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995;38:3806–12
   PubMed Web of Science ®Google Scholar
• Schnur RC, Corman ML, Gallaschun RJ, et al. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995;38:3813–20
   PubMed Web of Science ®Google Scholar
• Li Z, Jia L, Wang J, et al. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors. Eur J Med Chem 2014;87:346–63
   PubMed Web of Science ®Google Scholar
• Li Z, Jia L, Wang J, et al. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors. Eur J Med Chem 2014;85:359–70
   PubMed Web of Science ®Google Scholar
• Lu X, Xiao L, Wang L, et al. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem Pharmacol 2012;83:995–1004
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol 2012;65:471–517
   PubMedGoogle Scholar
• Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anti-cancer Drug Discov 2014;9:1–20
   PubMed Web of Science ®Google Scholar
• Xiong MP, Yanez JA, Kwon GS, et al. A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. J Pharm Sci-US 2009;98:1577–86
   PubMed Web of Science ®Google Scholar
• An WG, Schnur RC, Neckers L, et al. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 1997;40:60–4
   PubMed Web of Science ®Google Scholar
• Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anti-cancer activities. Cancer Lett 2010;290:24–35
   PubMed Web of Science ®Google Scholar
• Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharmaceut 2009;366:170–84
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54:S131–55
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Md S, Sahni JK, et al. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012;20:813–30
   PubMed Web of Science ®Google Scholar
• Muller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 2011;8:207–27
   PubMedGoogle Scholar
• Hong M, Zhu S, Jiang Y, et al. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles. J Control Release 2010;141:22–9
   PubMed Web of Science ®Google Scholar
• Kolate A, Baradia D, Patil S, et al. PEG – a versatile conjugating ligand for drugs and drug delivery systems. J Control Release 2014;192C:67–81
   Web of Science ®Google Scholar
• Owens DE, III Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharmaceut 2006;307:93–102
   PubMed Web of Science ®Google Scholar
• Jia L, Zhang D, Li Z, et al. Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloid Surface B 2010;80:213–18
   PubMed Web of Science ®Google Scholar
• Huang QL, Zhang LN, Cheung PCK, et al. Evaluation of sulfated alpha-glucans from Poria cocos mycelia as potential antitumor agent. Carbohyd Polym 2006;64:337–44
   Web of Science ®Google Scholar
• Liu L, Trimarchi JR, Keefe DL. Thiol oxidation-induced embryonic cell death in mice is prevented by the antioxidant dithiothreitol. Biol Reprod 1999;61:1162–9
   PubMed Web of Science ®Google Scholar